Lincoln Pharmaceuticals Ltd (LINCOLN) — FY26 Annual Report | 5 September 2026 (2 announcements)

Lincoln Pharmaceuticals reported FY2025-26 revenue of ₹671.03 crores, EBITDA of [amount context mismatch] crores, and net profit of [amount context mismatch] crores. The company highlighted growth through R&D, manufacturing expansion, and global market access, with strategic focus on quality and science. The 32nd AGM is scheduled for September 30, 2026, via video conference, with e-voting from September 26 to 29, 2025.

Lincoln Pharmaceuticals informed shareholders that letters with web links to access the FY2025-26 Annual Report are being sent to those without registered email addresses, directing them to the company website at https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/annual-report/#1676612189181-623364ff-dabe. The notice also reiterates the 32nd AGM scheduled for 30 September 2026 at 11:00 AM IST via video conference, and reminds physical security holders to update KYC details, including PAN, address, and bank information, to continue receiving communications and payments electronically from April 1, 2024.